Shigenori E. Nagai
Kita, 3620806, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
ILDR2 impairs antitumor surveillance by recruiting immunosuppressive CCR2+ monocytes.
Journal: Biochemical and biophysical research communications
Published: June 14, 2026
Targeting Habitual Fast Eating as a Modifiable Risk Factor for Type 2 Diabetes: A Propensity Score-Matched Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: June 12, 2026
Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE.
Journal: Breast (Edinburgh, Scotland)
Published: April 20, 2026
Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
Journal: Breast cancer (Tokyo, Japan)
Published: January 27, 2026
Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.
Journal: Breast (Edinburgh, Scotland)
Published: December 18, 2025
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.
Journal: Breast cancer research : BCR
Published: October 13, 2025
Impaired PD-1 expression in tumor-infiltrating senescent CD8+ T cells is reversed by PD-L1 blockade in a murine squamous cell carcinoma model.
Journal: Journal of oral biosciences
Published: September 19, 2025
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.
Journal: Breast cancer research and treatment
Published: September 12, 2025
Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.
Journal: Breast cancer (Tokyo, Japan)
Published: August 18, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: June 23, 2025
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).
Journal: Breast cancer (Tokyo, Japan)
Published: January 28, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: January 28, 2025
Last Updated: 09/26/2026